Group 1 - The biopharmaceutical industry is experiencing a recent correction after significant gains, particularly in the innovative drug and weight-loss drug sectors, which have seen the largest declines [1] - The SW biopharmaceutical sector has dropped by 5.05%, underperforming the CSI 300 index by approximately 6.43 percentage points during the same period [1] - All sub-sectors within the industry recorded negative returns, with medical consumables and hospital sectors experiencing smaller declines, while chemical preparations and offline pharmacy sectors faced larger drops [1] Group 2 - The biopharmaceutical ETF tracks the CS Biomedicine Index, which selects listed companies involved in biopharmaceuticals, medical devices, and medical services from the Shanghai and Shenzhen markets [2] - The CS Biomedicine Index, compiled by China Securities Index Co., Ltd., exhibits high industry concentration and growth characteristics, reflecting the overall performance of China's biopharmaceutical industry [2]
生物医药ETF（512290）涨超1.2%，减重药突破与估值低位引关注
Mei Ri Jing Ji Xin Wen·2025-07-01 05:59